Ardelyx reported total revenues of $2.25 million for the fourth quarter of 2019 and a net loss of $19.79 million. The company's cash, cash equivalents, and short-term investments are expected to fund operations until early 2022.
On track to submit NDA for Tenapanor for the control of serum phosphorus in mid-2020.
Total revenues were $5.3 million for the year ended December 31, 2019 related to the company’s ex-U.S. collaboration partnerships
Received FDA approval for IBSRELA® (tenapanor).
Raised approximately $135 million, net of underwriting discounts and commissions, following a successful underwritten public offering of 23,000,000 shares of common stock
Ardelyx maintains its expectation that its cash, cash equivalents and short-term investments will be sufficient to fund the company’s operations until early 2022 based on its current operating plans.
Analyze how earnings announcements historically affect stock price performance